Supportive Oligonucleotide Technique (SOT) has shown to be a very effective cancer support technique from clinical experience over the last 9 months, 85 patients and 151 doses given as of (7.25.13). This same methodology has been used in Europe for many years now.
A similar technique called antisense has been known and used for at least 15 years. However, there are distinctive differences between antisense (as traditionally used) and SOT.
SOT is not a genetic therapy, as is most antisense treatments and no genotoxic (chemo) drugs are used. RGCC-Labs uses mRNA's to only influence certain gene expressions not to change genetic structure. RGCC-labs uses mRNA expression fingerprinting in order to identify certain gene expression patterns as targets but without influence to the genetic structure (epigenetic). Based on this analysis RGCC-Labs uses the mRNA analysis of each individuals CTC's/CSC's and occasionally from biopsies of the tumor, and generates the SOT. As of today, following extensive searches, we know of no one or other entity making this type of technique this way anywhere in the world (as of 7.21.13).
SOT has the ability to induce apoptosis (cell death) in the CTC's, CSC's (circulating cancer tumor & stem cells) and ALL primary and metastatic tumors (regardless of size, and is able to cross the blood brain barrier with ease). SOT will remain active in the blood stream for approximately 14-16 weeks (maybe longer) per dose. Because, the mRNA actually features a stealth like ability that keeps the body from recognizing and destroying it. SOT will work 24/7 and has no decreased efficacy with any concurrent technique except chemotherapy and/or radiation.
Immune Support Therapy is an autologous process that involves the harvesting of peripheral blood Mononuclear cells from the patient’s own blood by a process called Leukopheresis. The cells are then cultured in the specialized and sophisticated laboratory in the presence of immune stimulatory agents (cytokines) and matured into dendritic cells by exposing them to the patient’s own inactivated tumor cells or with certain tumor specific proteins.
Matured dendritic cells are infused through IV to the patient to boost and fortify the immune system of the patient. It provides necessary impetus the body requires to fight back the cancer.
The heart of the dendritic cell process is the presentation of the immature dendritic cells with cancer specific tumor cells. Each cancer tumor has certain proteins that are phagocytosed by the dendritic cells and the Phagocytosed peptides are then presented on the surface of the dendritic cells for the activation and proliferation of the T cells. The T cells proliferate and secrete certain cytokines that act on the cancer cells. It is different from the conventional therapeutic modalities like surgery, chemotherapy and radiation therapy, as it is highly customised and tailor-made for individual patients and it amplifies the patient’s natural body defense mechanism.
WHAT KIND OF CANCERS CAN BE TREATED WITH IMMUNE SUPPORT THERAPY?
Theoretically, all solid cancers can be treated by dendritic cells. To date, therapeutic benefit has been documented in B cell lymphoma, myeloma, melanoma, head and neck, prostate cancer, colon cancer, ovarian cancer, breast cancer, and renal cell cancer amongst others.
AT WHAT CANCER STAGE SHOULD A PATIENT CONSIDER IMMUNE SUPPORT THERAPY?
The patient can consider Immune Support Therapy at any stage of the cancer.
HOW EFFECTIVE IS IMMUNE SUPPORT THERAPY?
Responses have generally been promising as it is an autologous process; it reduces cancer morbidity and improves the quality of life. Depending on the type of cancer and the functional status of patients the response may differ from patient to patient.
The information on this site is for Educational Purposes Only and is not designed to diagnose, treat, mitigate, prevent or cure any health conditions.
The U.S. Food and Drug Administration has not evaluated statements about these health topics or any suggested product compositions.